Avience Biomedicals IPO

These factors are Looking good: 1. Industry Tailwinds: The shift towards "Do-It-Yourself" rapid diagnostic testing for home use is a massive emerging trend. Future demand for at-home health monitoring is expected to soar, directly benefiting companies like Avience. 2. Capacity Expansion: The company is operating at high capacity 80-84% across all segments. They are aggressively reinvesting IPO funds to scale production, which signals strong management intent to capture market share. 3. Valuation Arbitrage: Based on current projections P/E 16-17 and P/B 2, the stock appears cheaper compared to industry peers like Qline Biotech, offering potential "upside cream" for investors. 4. Strong Management Experience: The leadership brings 30 years of experience, with over 15 years specifically in this niche diagnostic sector, suggesting operational seriousness. Key Risks Discussed: Equity Dilution: Promoters will hold 65% post-IPO; while acceptable, a significant drop in promoter stake in an SME company can be viewed as a negative signal regarding long-term ownership confidence. Trade Receivables/Cash Flow: As production scales, the company plans to offer more credit to clients to boost revenue. This may lead to higher outstanding receivables and potential liquidity strain. High Dependence on Outsourcing: A large portion of current revenue comes from "stock-in-trade" trading/buying and selling rather than pure manufacturing, which could pressure margins until internal capacity is fully online. Debt-to-Equity Ratio: The company is currently carrying debt to fuel its massive capital expenditure projects, which creates a levered balance sheet.